retatrutide nonalcoholic fatty liver disease nash trial Pharmacotherapy for NASH: Current and emerging Efficacy and safety of subcutaneous

Since the GHSR system also modulates other physiological functions such as GH secretion, it is necessary to expand understanding of the pathways involved and develop biased ligands to modulate only the therapeutically relevant signaling pathway (127)

GLP-1GLP-1 2

10.1038/s41598-019-45051-z 72 NerandzicM

So far, this effort has been a smashing success

Little to no weight change initially: Significant weight loss typically becomes more evident from weeks four to eight onwards, as the dose is increased and the body responds to sustained appetite reduction

High-sensitivity C-reactive protein in particular is a marker researchers watch closely, because chronic inflammation underpins so many of the conditions that excess weight drives